

## Statement of Advice:

**clostridium botulinum type A toxin-haemagglutinin complex 300 and 500 units (Dysport®)** **SMC No 1321/18**  
**Ipsen Ltd**

9 February 2018

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation

**clostridium botulinum type A toxin-haemagglutinin complex (Dysport®)** is not recommended for use within NHS Scotland.

**Indication under review:** Symptomatic treatment of focal spasticity of lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

**Chairman**  
**Scottish Medicines Consortium**